Τετάρτη 21 Μαρτίου 2018

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Cytoreductive nephrectomy is thought to improve survival in metastatic renal cell carcinoma (mRCC). As many patients are ineligible for major surgery, we hypothesized that SABR could be a safe alternative.

from Cancer via ola Kala on Inoreader http://ift.tt/2HR9WWN
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου